Antibody Drug Conjugate Therapeutics Market to Grow with Increasing Prevalence of Cancer

Growing prevalence of cancer is expected to be the major driver for the global antibody drug conjugate therapeutics market growth till 2026. According to the International Agency for Research on Cancer (IARC), in 2018, there were 18.1 million new cancer cases and deaths caused by cancer were estimated to be around 9.6 million. By 2030, these deaths are projected to reach 13 million, as per IARC estimates. The World Health Organization (WHO) predicts that new cancer cases will rise by 69% every year till 2030, causing a spike in the demand for antibody drug conjugate (ADC) therapeutics. The global antibody drug conjugate therapeutics market size will enlarge as a result.

Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/antibody-drug-conjugate-therapeutics-market-101172

Fortune Business Insights, through its report, titled “Antibody Drug Conjugate Therapeutics Market Size, Share and Global Trend By Mechanism of Action (HER2 Antibodies, CD30 Antibodies, Anti-CD33 Antibody, CD22 Antibody), By Disease Indication (Blood cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026”, brings out a comprehensive analysis of the market. The report also contains a detailed evaluation of the factors, trends, and other dynamics that will influence the development of the market during the forecast period.

Fortune Business Insights profiles some of the major players in the global antibody drug conjugate therapeutics market:
• Bayer AG
• Pfizer Inc.
• Hoffman-Le Roche Ltd
• Seattle Genetics Inc.
• ImmunoGen Inc.
• Genentech, Inc.
• Synthon Holding B.V.

Antibody Drug Conjugates (ADCs) are highly potent monoclonal substances linked chemically to a drug. They bind themselves on specific receptors or proteins found on certain cells, which includes cancer cells. The drug enters the concerned cells and kills them, but does not harm other healthy cells. This makes them the ideal solution to kill cancer cells.

Get PDF Brochure of this Report@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antibody-drug-conjugate-therapeutics-market-101172

Rising Incidence Rate of Chronic Diseases to Bolster Market Growth

The global antibody drug conjugate therapeutics market is poised to witness impressive growth in the coming decade as chronic diseases become commonplace worldwide. According to the WHO, deaths attributable to chronic diseases will 73% of all deaths and these diseases will be responsible for 60% of the global disease burden by 2020. The most widespread chronic diseases, the WHO states, will be cancer, type-2 diabetes, COPD, and cardiovascular diseases. This will result in a sharp rise in demand for ADCs and accelerate the global antibody drug conjugate therapeutics market revenue in the forecast period.

Increase in the Number of Breast Cancer Cases to Aid the Market

WHO figures reveal that breast cancer is one of the leading cancer deaths among women, affecting nearly 2.1 million women each year. In 2019, breast cancer killed around 627,000 women, according to the WHO, and the incidence rate of the disease is rising every year. This bodes well for the global antibody drug conjugates market size which will experience considerable expansion during the forecast period.

Growing Prevalence of Chronic Diseases to Drive the Market in Asia-Pacific

Among regions, North America and Europe are anticipated to exhibit robust growth owing to increasing investment in cancer research coupled with a well-established health insurance system. Asia-Pacific is projected to hold a sizeable portion in the global antibody drug conjugate therapeutics market share till 2026 as chronic diseases such as diabetes and cancer become more prevalent in the region.

Innovations and Collaborations to Spur Competition
Key players in the global antibody drug conjugate therapeutics market are increasingly focusing on developing novel products to strengthen their market position. For instance, Denmark-based biotech company, ADCendo, developed an ADC in August 2019 to treat metastatic soft tissue sarcoma. Additionally, companies are engaging in strategic collaborations to diversify their product portfolios. For example, UK-based AstraZeneca collaborated with Japan-based Daiichi Sankyo to develop an ADC that will deliver targeted treatment for cancer.

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact us:

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com

This release was published on openPR.